398 related articles for article (PubMed ID: 28623948)
1. One-carbon metabolism, cognitive impairment and CSF measures of Alzheimer pathology: homocysteine and beyond.
Dayon L; Guiraud SP; Corthésy J; Da Silva L; Migliavacca E; Tautvydaitė D; Oikonomidi A; Moullet B; Henry H; Métairon S; Marquis J; Descombes P; Collino S; Martin FJ; Montoliu I; Kussmann M; Wojcik J; Bowman GL; Popp J
Alzheimers Res Ther; 2017 Jun; 9(1):43. PubMed ID: 28623948
[TBL] [Abstract][Full Text] [Related]
2. Markers of neuroinflammation associated with Alzheimer's disease pathology in older adults.
Popp J; Oikonomidi A; Tautvydaitė D; Dayon L; Bacher M; Migliavacca E; Henry H; Kirkland R; Severin I; Wojcik J; Bowman GL
Brain Behav Immun; 2017 May; 62():203-211. PubMed ID: 28161476
[TBL] [Abstract][Full Text] [Related]
3. Plasma Proteomic Profiles of Cerebrospinal Fluid-Defined Alzheimer's Disease Pathology in Older Adults.
Dayon L; Wojcik J; Núñez Galindo A; Corthésy J; Cominetti O; Oikonomidi A; Henry H; Migliavacca E; Bowman GL; Popp J
J Alzheimers Dis; 2017; 60(4):1641-1652. PubMed ID: 29125490
[TBL] [Abstract][Full Text] [Related]
4. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
[TBL] [Abstract][Full Text] [Related]
5. Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database.
Ben Bouallègue F; Mariano-Goulart D; Payoux P;
Alzheimers Res Ther; 2017 Apr; 9(1):32. PubMed ID: 28441967
[TBL] [Abstract][Full Text] [Related]
6. Homocysteine metabolism and cerebrospinal fluid markers for Alzheimer's disease.
Popp J; Lewczuk P; Linnebank M; Cvetanovska G; Smulders Y; Kölsch H; Frommann I; Kornhuber J; Maier W; Jessen F
J Alzheimers Dis; 2009; 18(4):819-28. PubMed ID: 19661622
[TBL] [Abstract][Full Text] [Related]
7. Dimethylarginines, homocysteine metabolism, and cerebrospinal fluid markers for Alzheimer's disease.
Arlt S; Schwedhelm E; Kölsch H; Jahn H; Linnebank M; Smulders Y; Jessen F; Böger RH; Popp J
J Alzheimers Dis; 2012; 31(4):751-8. PubMed ID: 22710910
[TBL] [Abstract][Full Text] [Related]
8. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.
Karikari TK; Pascoal TA; Ashton NJ; Janelidze S; Benedet AL; Rodriguez JL; Chamoun M; Savard M; Kang MS; Therriault J; Schöll M; Massarweh G; Soucy JP; Höglund K; Brinkmalm G; Mattsson N; Palmqvist S; Gauthier S; Stomrud E; Zetterberg H; Hansson O; Rosa-Neto P; Blennow K
Lancet Neurol; 2020 May; 19(5):422-433. PubMed ID: 32333900
[TBL] [Abstract][Full Text] [Related]
9. Plasma neurofilament light and phosphorylated tau 181 as biomarkers of Alzheimer's disease pathology and clinical disease progression.
Clark C; Lewczuk P; Kornhuber J; Richiardi J; Maréchal B; Karikari TK; Blennow K; Zetterberg H; Popp J
Alzheimers Res Ther; 2021 Mar; 13(1):65. PubMed ID: 33766131
[TBL] [Abstract][Full Text] [Related]
10. Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age.
Sutphen CL; Jasielec MS; Shah AR; Macy EM; Xiong C; Vlassenko AG; Benzinger TL; Stoops EE; Vanderstichele HM; Brix B; Darby HD; Vandijck ML; Ladenson JH; Morris JC; Holtzman DM; Fagan AM
JAMA Neurol; 2015 Sep; 72(9):1029-42. PubMed ID: 26147946
[TBL] [Abstract][Full Text] [Related]
11. Associations between cerebral small-vessel disease and Alzheimer disease pathology as measured by cerebrospinal fluid biomarkers.
Kester MI; Goos JD; Teunissen CE; Benedictus MR; Bouwman FH; Wattjes MP; Barkhof F; Scheltens P; van der Flier WM
JAMA Neurol; 2014 Jul; 71(7):855-62. PubMed ID: 24818585
[TBL] [Abstract][Full Text] [Related]
12. Biomarkers as predictors for conversion from mild cognitive impairment to Alzheimer-type dementia: implications for trial design.
van Rossum IA; Vos S; Handels R; Visser PJ
J Alzheimers Dis; 2010; 20(3):881-91. PubMed ID: 20413876
[TBL] [Abstract][Full Text] [Related]
13. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study.
Hansson O; Zetterberg H; Buchhave P; Londos E; Blennow K; Minthon L
Lancet Neurol; 2006 Mar; 5(3):228-34. PubMed ID: 16488378
[TBL] [Abstract][Full Text] [Related]
14. Folate and homocysteine in the cerebrospinal fluid of patients with Alzheimer's disease or dementia: a case control study.
Smach MA; Jacob N; Golmard JL; Charfeddine B; Lammouchi T; Ben Othman L; Dridi H; Bennamou S; Limem K
Eur Neurol; 2011; 65(5):270-8. PubMed ID: 21474939
[TBL] [Abstract][Full Text] [Related]
15. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.
Sunderland T; Mirza N; Putnam KT; Linker G; Bhupali D; Durham R; Soares H; Kimmel L; Friedman D; Bergeson J; Csako G; Levy JA; Bartko JJ; Cohen RM
Biol Psychiatry; 2004 Nov; 56(9):670-6. PubMed ID: 15522251
[TBL] [Abstract][Full Text] [Related]
16. Multiple Effect of APOE Genotype on Clinical and Neuroimaging Biomarkers Across Alzheimer's Disease Spectrum.
Liu Y; Tan L; Wang HF; Liu Y; Hao XK; Tan CC; Jiang T; Liu B; Zhang DQ; Yu JT;
Mol Neurobiol; 2016 Sep; 53(7):4539-47. PubMed ID: 26298664
[TBL] [Abstract][Full Text] [Related]
17. Alzheimer disease pathology and the cerebrospinal fluid proteome.
Dayon L; Núñez Galindo A; Wojcik J; Cominetti O; Corthésy J; Oikonomidi A; Henry H; Kussmann M; Migliavacca E; Severin I; Bowman GL; Popp J
Alzheimers Res Ther; 2018 Jul; 10(1):66. PubMed ID: 30021611
[TBL] [Abstract][Full Text] [Related]
18. Homocysteine metabolism is associated with cerebrospinal fluid levels of soluble amyloid precursor protein and amyloid beta.
Oikonomidi A; Lewczuk P; Kornhuber J; Smulders Y; Linnebank M; Semmler A; Popp J
J Neurochem; 2016 Oct; 139(2):324-332. PubMed ID: 27507672
[TBL] [Abstract][Full Text] [Related]
19. Time course of phosphorylated-tau181 in blood across the Alzheimer's disease spectrum.
Moscoso A; Grothe MJ; Ashton NJ; Karikari TK; Rodriguez JL; Snellman A; Suárez-Calvet M; Zetterberg H; Blennow K; Schöll M;
Brain; 2021 Feb; 144(1):325-339. PubMed ID: 33257949
[TBL] [Abstract][Full Text] [Related]
20. Determinants of the essential one-carbon metabolism metabolites, homocysteine, S-adenosylmethionine, S-adenosylhomocysteine and folate, in cerebrospinal fluid.
Smith DE; Smulders YM; Blom HJ; Popp J; Jessen F; Semmler A; Farkas M; Linnebank M
Clin Chem Lab Med; 2012 Mar; 50(9):1641-7. PubMed ID: 22962226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
